174 related articles for article (PubMed ID: 15004537)
1. Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.
Coyne RS; McDonald HB; Edgemon K; Brody LC
Cancer Biol Ther; 2004 May; 3(5):453-7. PubMed ID: 15004537
[TBL] [Abstract][Full Text] [Related]
2. Methods to classify BRCA1 variants of uncertain clinical significance: the more the merrier.
Billack B; Monteiro AN
Cancer Biol Ther; 2004 May; 3(5):458-9. PubMed ID: 15118412
[No Abstract] [Full Text] [Related]
3. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
[TBL] [Abstract][Full Text] [Related]
4. Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.
Millot GA; Berger A; Lejour V; Boulé JB; Bobo C; Cullin C; Lopes J; Stoppa-Lyonnet D; Nicolas A
Hum Mutat; 2011 Dec; 32(12):1470-80. PubMed ID: 21922593
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
Vallon-Christersson J; Cayanan C; Haraldsson K; Loman N; Bergthorsson JT; Brøndum-Nielsen K; Gerdes AM; Møller P; Kristoffersson U; Olsson H; Borg A; Monteiro AN
Hum Mol Genet; 2001 Feb; 10(4):353-60. PubMed ID: 11157798
[TBL] [Abstract][Full Text] [Related]
6. Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing.
Humphrey JS; Salim A; Erdos MR; Collins FS; Brody LC; Klausner RD
Proc Natl Acad Sci U S A; 1997 May; 94(11):5820-5. PubMed ID: 9159158
[TBL] [Abstract][Full Text] [Related]
7. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Hayes F; Cayanan C; Barillà D; Monteiro AN
Cancer Res; 2000 May; 60(9):2411-8. PubMed ID: 10811118
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants.
Di Cecco L; Melissari E; Mariotti V; Iofrida C; Galli A; Guidugli L; Lombardi G; Caligo MA; Iacopetti P; Pellegrini S
Eur J Cancer; 2009 Aug; 45(12):2187-96. PubMed ID: 19493677
[TBL] [Abstract][Full Text] [Related]
9. Validation and Data-Integration of Yeast-Based Assays for Functional Classification of BRCA1 Missense Variants.
Bellè F; Mercatanti A; Lodovichi S; Congregati C; Guglielmi C; Tancredi M; Caligo MA; Cervelli T; Galli A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409408
[TBL] [Abstract][Full Text] [Related]
10. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
12. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
[TBL] [Abstract][Full Text] [Related]
14. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
Williams RS; Chasman DI; Hau DD; Hui B; Lau AY; Glover JN
J Biol Chem; 2003 Dec; 278(52):53007-16. PubMed ID: 14534301
[TBL] [Abstract][Full Text] [Related]
15. Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
Lodovichi S; Vitello M; Cervelli T; Galli A
Cell Cycle; 2016 Oct; 15(20):2723-31. PubMed ID: 27484786
[TBL] [Abstract][Full Text] [Related]
16. CRIMEtoYHU: a new web tool to develop yeast-based functional assays for characterizing cancer-associated missense variants.
Mercatanti A; Lodovichi S; Cervelli T; Galli A
FEMS Yeast Res; 2017 Dec; 17(8):. PubMed ID: 29069390
[TBL] [Abstract][Full Text] [Related]
17. Functional and structural analysis of C-terminal BRCA1 missense variants.
Quiles F; Fernández-Rodríguez J; Mosca R; Feliubadaló L; Tornero E; Brunet J; Blanco I; Capellá G; Pujana MÀ; Aloy P; Monteiro A; Lázaro C
PLoS One; 2013; 8(4):e61302. PubMed ID: 23613828
[TBL] [Abstract][Full Text] [Related]
18. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Drikos I; Nounesis G; Vorgias CE
Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
[TBL] [Abstract][Full Text] [Related]
20. Classification of BRCA1 missense variants of unknown clinical significance.
Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
